Abstract
Results of the SELECT-PsA 1 trial suggest the selective Janus kinase inhibitor upadacitinib shows promise for the treatment of psoriatic arthritis.
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
